Stock Quote MOUA - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

Bid

Ask

Volume

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Previous Close

Open

Last Trade

Last Trade Time

Average Volume (3m)

Financial Volume

VWAP

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update

$478 million in second quarter global net product sales First CIDP patients treated with VYVGART® Hytrulo following June 21st FDA approval On track to begin four additional registrational...

argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024

July 18, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in...

Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod...

argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting

ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of...

argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP) First novel, precision mechanism of action in...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
JWNGJaywing Plc	3.00p (114.29%)	3.16M
STXShield Therapeutics Plc	2.65p (32.50%)	13.67M
MTROMetro Bank Holdings Plc	52.20p (29.85%)	17.77M
ECHOEcho Energy Plc	0.0041p (28.13%)	19.41B
CRSCrystal Amber Fund Limited	108.00p (20.00%)	118.22k
MSMNMosman Oil And Gas Limited	0.0425p (-24.11%)	1.53B
UKOGUk Oil & Gas Plc	0.0585p (-23.03%)	2.83B
UKRUkrproduct Group Limited	2.70p (-19.40%)	118.06k
MCONMincon Group Plc	35.00p (-18.60%)	172.2k
TUNTungsten West Plc	2.25p (-18.18%)	929.3k
ECHOEcho Energy Plc	0.0041p (28.13%)	19.41B
UKOGUk Oil & Gas Plc	0.0585p (-23.03%)	2.83B
MSMNMosman Oil And Gas Limited	0.0425p (-24.11%)	1.53B
VELAVela Technologies Plc	0.0095p (11.76%)	480.54M
GWMOGreat Western Mining Corporation Plc	0.0465p (-3.13%)	405.31M